journal article·2023-08-23

Compartmentalized Nano-MOFs as Co-delivery Systems for Enhanced Antitumor Therapy

Wenxiu Duan, Lifeng Hang, Yinchu Ma, Qin Wang, Xinfeng Tang, Wei Jiang, Yi Wu, Weifu Lv, Yucai Wang

ACS Applied Materials & Interfaces· Volume 15· Issue 33
Publisher page

Abstract

Therapeutic bioactive macromolecules hold great promise in cancer therapy, but challenges such as low encapsulation efficiency and susceptibility to inactivation during the targeted co-delivery hinder their widespread applications. Compartmentalized nano-metal-organic frameworks (nMOFs) can easily load macromolecules in the innermost layer, protect them from the outside environment, and selectively release them in the target location after stimulation, showing great potential in the co-delivery of biomacromolecules. Herein, the rationally designed (GOx + CAT)/ZIF-8@BSA TPZ /ZIF-8 (named GCZ@BTZ) nMOFs with compartmentalized structures are employed to deliver cascaded enzymes and the chemotherapeutic drug tirapazamine (TPZ)-conjugated bovine serum albumin (BSA TPZ ). Benefiting from the compartmentalized structure and protective shell, the GCZ@BTZ system is stable during blood circulation and preferentially accumulates in the tumor. Furthermore, in response to the acidic tumor environment, GCZ@BTZ effectively released the loading enzymes and BSA TPZ . Along with the tumor starvation caused by depletion of glucose, cascaded reactions could also contribute to the enhancement of tumor hypoxia, which further activated BSA TPZ -based chemotherapy. Notably, in the mouse tumor models, GCZ@BTZ treatment significantly inhibits tumor survival and metastasis. Such a compartmentalized nMOF delivery system presents a promising avenue for the efficient delivery of bioactive macromolecules.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Peptidase Inhibition and Analysis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Radiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China

The Department of Medical Imaging, Guangdong Second Provincial General Hospital, Guangzhou 518037, China

Wuxi School of Medicine, Jiangnan University, WuXi 214122, China

The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences and Medical Center, University of Science and Technology of China, Hefei 230027, P. R. China

Intelligent Nanomedicine Institute, the First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China

Funding

National Key Research and Development Program of China · China Postdoctoral Science Foundation · Fundamental Research Funds for the Central Universities · National Natural Science Foundation of China · Natural Science Foundation of Anhui Province · Collaborative Innovation Project of Colleges and Universities of Anhui Province

References (45)

Show source-provided references
1. 10.1021/acs.nanolett.8b0263910.1021/acs.nanolett.8b02639 ↗
2. 10.1007/s12274-017-1898-310.1007/s12274-017-1898-3 ↗
3. 10.1021/acsabm.0c0162310.1021/acsabm.0c01623 ↗
4. 10.1016/j.ijbiomac.2019.09.02010.1016/j.ijbiomac.2019.09.020 ↗
5. 10.1021/acsnano.8b0785810.1021/acsnano.8b07858 ↗
6. 10.1039/d1cs00343g10.1039/d1cs00343g ↗
7. 10.1002/anie.20191639010.1002/anie.201916390 ↗
8. 10.1002/anie.20161030210.1002/anie.201610302 ↗
9. 10.1016/j.vaccine.2022.05.06810.1016/j.vaccine.2022.05.068 ↗
10. 10.1016/j.jconrel.2022.06.01410.1016/j.jconrel.2022.06.014 ↗
11. 10.1039/c8cs00606g10.1039/c8cs00606g ↗
12. 10.1016/j.addr.2021.11407910.1016/j.addr.2021.114079 ↗
13. 10.1021/acs.nanolett.0c0375610.1021/acs.nanolett.0c03756 ↗
14. 10.3390/polym1307102710.3390/polym13071027 ↗
15. 10.1021/acsami.2c2001910.1021/acsami.2c20019 ↗
16. 10.1016/j.ijbiomac.2022.09.23910.1016/j.ijbiomac.2022.09.239 ↗
17. 10.1016/j.jconrel.2020.07.02110.1016/j.jconrel.2020.07.021 ↗
18. 10.1039/c8tb02484g10.1039/c8tb02484g ↗
19. 10.7150/thno.5493010.7150/thno.54930 ↗
20. 10.1021/acsabm.1c0044710.1021/acsabm.1c00447 ↗
21. 10.1007/s12274-020-3179-910.1007/s12274-020-3179-9 ↗
22. 10.1039/d1cs01011e10.1039/d1cs01011e ↗
23. 10.1038/s41929-018-0117-210.1038/s41929-018-0117-2 ↗
24. 10.1021/acs.chemmater.7b0497710.1021/acs.chemmater.7b04977 ↗
25. 10.1039/c8sc00825f10.1039/c8sc00825f ↗
26. 10.1007/s12274-017-1874-y10.1007/s12274-017-1874-y ↗
27. 10.1038/nmat481510.1038/nmat4815 ↗
28. 10.1038/ncomms824010.1038/ncomms8240 ↗
29. 10.1039/c8dt01789a10.1039/c8dt01789a ↗
30. 10.1002/smll.20210231510.1002/smll.202102315 ↗
31. 10.1038/s41467-021-25970-010.1038/s41467-021-25970-0 ↗
32. 10.1021/acsami.2c1847310.1021/acsami.2c18473 ↗
33. 10.1021/acsami.9b2352610.1021/acsami.9b23526 ↗
34. 10.1021/acsami.1c1550610.1021/acsami.1c15506 ↗
35. 10.1002/anie.20211410010.1002/anie.202114100 ↗
36. 10.1021/acsami.0c1642810.1021/acsami.0c16428 ↗
37. 10.1021/jacs.6b0141410.1021/jacs.6b01414 ↗
38. 10.1021/acs.cgd.6b0116110.1021/acs.cgd.6b01161 ↗
39. 10.1021/acsnano.9b0246610.1021/acsnano.9b02466 ↗
40. 10.1021/acsami.8b1348710.1021/acsami.8b13487 ↗
41. 10.1021/jacs.8b0445710.1021/jacs.8b04457 ↗
42. 10.1002/smll.20210773210.1002/smll.202107732 ↗
43. 10.1002/smll.20200586510.1002/smll.202005865 ↗
44. 10.1002/anie.20171041810.1002/anie.201710418 ↗
45. 10.7150/thno.3826110.7150/thno.38261 ↗